Brigatinib monotherapy may be a potential treatment for NSCLC harboring del19/T790M/cis-C797S mutations based on preclinical studies; however, no clinical report has evaluated its efficacy on <i>EGFR</i> del19/T790M/cis-C797S mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.